X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
(GLPH)
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
| % ch | % | -0.3 |
| No. of shares | m | 271.28 |
| % ch week | % | -1.8 |
| % ch 1-mth | % | -6.4 |
| % ch 12-mth | % | -19.4 |
| 52 week H/L | Rs | 993.0/600.0 |
| No. of Mths Year Ending |
12 Mar-12* |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
5-Yr Chart Click to enlarge
|
|---|
| GLENMARK PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 351 | 551 | 612 | 879 | 1,262 | |
| Low | Rs | 263 | 301 | 464 | 752 | 672 | |
| Sales per share (Unadj.) | Rs | 148.6 | 185.1 | 221.4 | 244.4 | 270.6 | |
| Earnings per share (Unadj.) | Rs | 17.2 | 23.2 | 20.1 | 17.5 | 24.9 | |
| Diluted earnings per share | Rs | 17.1 | 23.2 | 20.1 | 17.5 | 25.9 | |
| Cash flow per share (Unadj.) | Rs | 20.8 | 27.9 | 28.1 | 27.1 | 34.4 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Adj. dividends per share | Rs | 1.99 | 2.00 | 2.00 | 2.00 | 2.08 | |
| Dividend yield (eoy) | % | 0.7 | 0.5 | 0.4 | 0.2 | 0.2 | |
| Book value per share (Unadj.) | Rs | 88.8 | 102.0 | 110.0 | 110.6 | 151.3 | |
| Adj. book value per share | Rs | 88.5 | 101.9 | 110.0 | 110.6 | 157.4 | |
| Shares outstanding (eoy) | m | 270.53 | 270.85 | 271.22 | 271.29 | 282.16 | |
| Bonus/Rights/Conversions | ESOS | - | - | - | - | ||
| Price / Sales ratio | x | 2.1 | 2.3 | 2.4 | 3.3 | 3.6 | |
| Avg P/E ratio | x | 17.9 | 18.4 | 26.7 | 46.6 | 38.9 | |
| P/CF ratio (eoy) | x | 14.8 | 15.3 | 19.1 | 30.1 | 28.1 | |
| Price / Book Value ratio | x | 3.5 | 4.2 | 4.9 | 7.4 | 6.4 | |
| Dividend payout | % | 11.7 | 8.6 | 9.9 | 11.4 | 8.0 | |
| Avg Mkt Cap | Rs m | 83,053 | 115,355 | 145,889 | 221,284 | 272,778 | |
| No. of employees | `000 | NA | NA | NA | 9.5 | 10.0 | |
| Total wages/salary | Rs m | 6,289 | 7,830 | 10,262 | 12,024 | 13,782 | |
| Avg. sales/employee | Rs Th | NM | NM | NM | 6,961.1 | 7,614.9 | |
| Avg. wages/employee | Rs Th | NM | NM | NM | 1,262.5 | 1,374.8 | |
| Avg. net profit/employee | Rs Th | NM | NM | NM | 499.0 | 700.2 | |
| GLENMARK PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 40,206 | 50,123 | 60,052 | 66,298 | 76,340 | |
| Other income | Rs m | 182 | 108 | 115 | 219 | 356 | |
| Total revenues | Rs m | 40,388 | 50,231 | 60,167 | 66,516 | 76,696 | |
| Gross profit | Rs m | 7,144 | 10,153 | 10,908 | 10,225 | 14,172 | |
| Depreciation | Rs m | 979 | 1,270 | 2,168 | 2,600 | 2,691 | |
| Interest | Rs m | 1,466 | 1,600 | 1,886 | 1,902 | 1,789 | |
| Profit before tax | Rs m | 4,881 | 7,390 | 6,969 | 5,943 | 10,048 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 238 | 1,107 | 1,513 | 1,190 | 3,028 | |
| Profit after tax | Rs m | 4,643 | 6,283 | 5,456 | 4,752 | 7,019 | |
| Gross profit margin | % | 17.8 | 20.3 | 18.2 | 15.4 | 18.6 | |
| Effective tax rate | % | 4.9 | 15.0 | 21.7 | 20.0 | 30.1 | |
| Net profit margin | % | 11.5 | 12.5 | 9.1 | 7.2 | 9.2 | |
| GLENMARK PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 29,472 | 37,268 | 47,627 | 53,233 | 59,096 | |
| Current liabilities | Rs m | 19,017 | 22,014 | 29,492 | 37,113 | 40,018 | |
| Net working cap to sales | % | 26.0 | 30.4 | 30.2 | 24.3 | 25.0 | |
| Current ratio | x | 1.5 | 1.7 | 1.6 | 1.4 | 1.5 | |
| Inventory Days | Days | 72 | 61 | 57 | 70 | 75 | |
| Debtors Days | Days | 113 | 119 | 131 | 138 | 119 | |
| Net fixed assets | Rs m | 24,248 | 27,682 | 30,357 | 32,704 | 39,075 | |
| Share capital | Rs m | 271 | 271 | 271 | 271 | 282 | |
| "Free" reserves | Rs m | 15,789 | 19,338 | 21,415 | 17,563 | 30,281 | |
| Net worth | Rs m | 24,016 | 27,630 | 29,833 | 30,003 | 42,703 | |
| Long term debt | Rs m | 13,125 | 19,203 | 24,287 | 25,744 | 24,873 | |
| Total assets | Rs m | 54,660 | 71,710 | 86,336 | 96,875 | 111,026 | |
| Interest coverage | x | 4.3 | 5.6 | 4.7 | 4.1 | 6.6 | |
| Debt to equity ratio | x | 0.5 | 0.7 | 0.8 | 0.9 | 0.6 | |
| Sales to assets ratio | x | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Return on assets | % | 11.2 | 11.0 | 8.5 | 6.9 | 7.9 | |
| Return on equity | % | 19.3 | 22.7 | 18.3 | 15.8 | 16.4 | |
| Return on capital | % | 17.1 | 19.2 | 16.4 | 14.1 | 17.5 | |
| Exports to sales | % | 13.4 | 11.9 | 11.7 | 44.8 | 43.3 | |
| Imports to sales | % | 0.9 | 1.7 | 1.0 | 7.1 | 7.4 | |
| Exports (fob) | Rs m | 5,406 | 5,957 | 7,039 | 29,720 | 33,044 | |
| Imports (cif) | Rs m | 347 | 858 | 579 | 4,680 | 5,672 | |
| Fx inflow | Rs m | 5,662 | 7,007 | 8,528 | 31,299 | 36,945 | |
| Fx outflow | Rs m | 2,364 | 4,135 | 3,641 | 10,856 | 61,066 | |
| Net fx | Rs m | 3,298 | 2,872 | 4,888 | 20,443 | -24,122 | |
| GLENMARK PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 8,044 | 6,479 | 8,537 | 4,817 | 3,449 | |
| From Investments | Rs m | -2,778 | -4,641 | -3,681 | -5,400 | -8,802 | |
| From Financial Activity | Rs m | -3,614 | 1,952 | -980 | 1,992 | 6,986 | |
| Net Cashflow | Rs m | 1,252 | 2,851 | 1,896 | -311 | 934 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
More Pharmaceuticals Company Fact Sheets: WOCKHARDT LTD. SUVEN LIFE MERCK LTD WYETH LTD SANOFI INDIA
Compare GLENMARK PHARMA With: WOCKHARDT LTD. SUVEN LIFE MERCK LTD WYETH LTD SANOFI INDIA
Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Profit booking continued in the afternoon session in the Indian share markets amid weak European cues. At the closing bell, the BSE Sensex stood lower by 153 points.
Base price erosion in the US and lower Zetia sales impacts profits.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.
US markets decline while other geographies grow in the quarter.
Currency fluctuation and one time provision impacts operating margins.
More Views on NewsWhich brings us back to the basic question, why was demonetisation carried out?
Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?
Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.
Trading is not synonymous with mutual funds, PersonalFN explains.
RBI and government at loggerheads over interest rates.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
